WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 555401
CAS#: 610318-54-2 (free form)
Description: RGX-104, also known as SB 742881, is a liver X receptor beta agonist with potential immunomodulating and antineoplastic activities. Upon oral administration, RGX-104 selectively targets and binds to LXRbeta, thereby activating LXRbeta-mediated signaling, leading to the transcription of certain tumor suppressor genes and the downregulation of certain tumor promoter genes. This particularly activates the expression of apolipoprotein E (ApoE), a tumor suppressor protein, in tumor cells and certain immune cells. This activates the innate immune system, resulting in depletion of immunosuppressive myeloid-derived suppressor cells (MDSCs), tumor cells and endothelial cells in the tumor microenvironment. This reverses immune evasion, enhances anti-tumor immune responses and inhibits proliferation of tumor cells.
MedKoo Cat#: 555401
Name: RGX-104 free form
CAS#: 610318-54-2 (free form)
Chemical Formula: C34H33ClF3NO3
Exact Mass: 595.2101
Molecular Weight: 596.0872
Elemental Analysis: C, 68.51; H, 5.58; Cl, 5.95; F, 9.56; N, 2.35; O, 8.05
Related CAS #: 610318-54-2 (free form) 610318-03-1 (HCl)
Synonym: Abequolixron; RGX-104 free form, RGX-104; RGX104; RGX 104; SB742881; SB-742881; SB 742881;
IUPAC/Chemical Name: (R)-2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-3-methylpropoxy]phenyl]acetic acid
InChi Key: ZLJZDYOBXVOTSA-XMMPIXPASA-N
InChi Code: InChI=1S/C34H33ClF3NO3/c1-24(18-19-42-29-16-8-10-25(20-29)21-32(40)41)39(22-28-15-9-17-31(33(28)35)34(36,37)38)23-30(26-11-4-2-5-12-26)27-13-6-3-7-14-27/h2-17,20,24,30H,18-19,21-23H2,1H3,(H,40,41)/t24-/m1/s1
SMILES Code: O=C(O)CC1=CC=CC(OCC[C@H](N(CC2=CC=CC(C(F)(F)F)=C2Cl)CC(C3=CC=CC=C3)C4=CC=CC=C4)C)=C1
1: Aravindhan K, Webb CL, Jaye M, Ghosh A, Willette RN, DiNardo NJ, Jucker BM.
Assessing the effects of LXR agonists on cellular cholesterol handling: a stable
isotope tracer study. J Lipid Res. 2006 Jun;47(6):1250-60. Epub 2006 Mar 27.
PubMed PMID: 16567856.
2: Groot PH, Pearce NJ, Yates JW, Stocker C, Sauermelch C, Doe CP, Willette RN,
Olzinski A, Peters T, d'Epagnier D, Morasco KO, Krawiec JA, Webb CL, Aravindhan
K, Jucker B, Burgert M, Ma C, Marino JP, Collins JL, Macphee CH, Thompson SK,
Jaye M. Synthetic LXR agonists increase LDL in CETP species. J Lipid Res. 2005
Oct;46(10):2182-91. Epub 2005 Jul 16. PubMed PMID: 16024916.